Thank you for subscribing to the Free Monthly Stock Pick. This month’s pick is posted below, and future Picks will be sent by email. The Pick is Not a recommendation. We only recommend a portfolio approach for investing. The pick is either part of our model portfolio or a high-rated pick if the Portfolio is in Cash. The next Opening Price after publication is used to calculate performance.
Complete access to the Model Portfolio is available with a paid subscription.
Remember, there is a 60-day money back guarantee. So you can always try out.
Sample issues are further below.
Stock Pick for May 2023: no pick (market conditions)
Stock Pick for Apr 2023: AUPH +9%
Stock Pick for Mar 2023: no pick (market conditions)
Stock Pick for Feb 2023: ISEE 0%
Stock Pick for Jan 2023: FDMT 0%
Stock Pick for Dec 2022: RYTM +4%
Stock Pick for Nov 2022: AKRO +7%
Stock Pick for Oct 2022: PLRX +19%
Stock Pick for Sep 2022: no pick
Stock Pick for Aug 2022: CTIC -7%
Stock Pick for Jul 2022: XENE +3%
Stock Pick for May & Jun 2022: no picks
Stock Pick for Apr 2022: ITCI -19%
Stock Pick for Mar 2022: KZR +3%
Stock Pick for Feb 2022: No Pick
Stock Pick for Jan 2022: INBX -29% (closed Jan 18)
Stock Pick for Nov/Dec 2022: CCXI +1%
Stock Pick for Sep and Oct 2021: CYTK +4%
Stock Pick for Aug 2021: AGEN +14%
Stock Pick for Jul 2021: ARVN +29%
The Monthly Stock Pick for Jun 2021: SAVA +53%
The Monthly Stock Pick for May 2021: RUBY -2%
The Monthly Stock Pick for Apr 2021: PRTA +6%
The Monthly Stock Pick for Mar 2021: GRTS -29%
The Monthly Stock Pick for Feb 2021: CLDX +32%
The Monthly Stock Pick for Jan 2021: SRRK +26%
Building Investment Wealth Over Time
Model Portfolio History
Interested in more Samples?
You can view them here
(scroll towards the bottom of that page)
A System-driven Approach to Investing and Building Wealth
It's Time to Capture the Potential of Biotechs, Leveraging
Quantitative Techniques Like Hedge Funds Do ...
Our BioTechQuant System Recommends a Model Portfolio with
a Strong Track Record of Returns, Far Outpacing Benchmarks
Graycell Advisors, and its affiliates, officers, employees, families, and all other related parties, collectively referred to as ‘Graycell’ and/or ‘we,’ is a publisher of financial information, such as the Smallcap, and Prudent Biotech newsletters. We are not a Registered Investment Advisor (RIA). Historical performance figures provided are hypothetical and unaudited, and based on our proprietary analysis and system performance, back-tested over a period of time. Hypothetical or simulated performance results have limitations, and unlike an actual performance record, simulated results do not represent actual trading and consequently do not involve financial risk of actual trading. The performance results obtained are intended for illustrative purposes only. No representation is being made that an account will or is likely to achieve profit or losses similar to those shown. Past performance is not indicative of future results, which may vary. All stock and related investments have a degree of risk, which can result in a significant or total loss. In addition, biotech sector and smallcaps are characterized by much higher risk and volatility than the general stock market.
Information contained herein is general and does not constitute a personal recommendation or takes into account the particular investment objectives, financial situations, or needs of individual investors. If you decide to invest in any of the stocks of the companies mentioned in the newsletters, samples, alerts, etc., sent to you or available on our websites, you can and may lose some or all of your investment. You alone are responsible for your investment decisions. Use of the information herein is at one's own risk. We are simply sharing the results of our model.
Nothing should be construed as a recommendation or an offer to buy or sell any securities, and we are not liable nor do we assume any liability or responsibility for losses incurred as a result of any information provided or not provided or not made available in a timely manner, herein or on our website or using any other medium. We cannot guarantee the accuracy and completeness of any information furnished by us.
We may or may not have existing positions in the stocks mentioned in our reports. Our models are proprietary and/or licensed, and can be changed or revised based on our discretion at any time without any notification. Subscribers and investors should always conduct their own due diligence with any potential investment, and consider obtaining professional advice before making an investment decision.
© Graycell Advisors. All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the written permission of Graycell Advisors is strictly prohibited and shall be deemed to be copyright infringement.